SMART MONEY GROUP

[A go go]

07:43 AM EDT, 07/27/2020 (MT Newswires) -- MediciNova (MNOV) said Monday it has obtained exclusive worldwide rights to develop BC-PIV, a human parainfluenza virus type 2 vector, into a potential vaccine against SARS-CoV-2, the virus that causes COVID-19.

BC-PIV was co-developed by BioComo and Mie University Japan. It can be developed as an intra-nasal vaccine in addition to an intra-muscular injection, according to BioComo.

The details of the deal weren't disclosed. MediciNova is also developing MN-166 as a potential treatment for acute respiratory distress syndrome in patients with COVID-19.

MNOV climbed 11% in premarket trading on Monday.

Price: 6.27, Change: +0.63, Percent Change: +11.17

http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.